While anal cancer is relatively uncommon in the general population, its incidence is substantially elevated in certain groups, including patients with HIV and certain autoimmune conditions.
The BLA is supported by data from the POD1UM-202 trial that evaluated retifanlimab in 94 adults with locally advanced or metastatic SCAC who progressed after platinum-based chemotherapy.
As Crohn disease perianal fistulas often do not respond to available treatments, researchers developed a patient-derived quality-of-life tool to evaluate the impact of the condition on patients.
Short-course radiotherapy followed by chemotherapy and total mesorectal excision improved outcomes for patients with high-risk locally advanced rectal cancer.
If the current COVID-19 trends persist, the NCI estimates that the pandemic’s impact could threaten the trend of annually decreasing cancer mortality seen in the US since 1990.
Digital manometry provides similar pressure readings compared with the gold-standard high-resolution anorectal manometry in patients with chronic constipation and fecal incontinence.
Survival and recurrence rates were not significantly different between patients with low rectal cancer who were treated with either local or total mesorectal excision.
Stool banks may guarantee reliable, timely and equitable access to fecal microbiota transplantation for patients and a traceable workflow that ensures safety and quality of procedures.
This study provides normative values for the bilateral lumbar and sacral-anorectal MEPs in healthy subject with no age or gender influence on rectal or anal MEP latency.
An interdisciplinary group treatment for fecal incontinence in children (called “Poop group” by investigators) is a promising alternative for up to 60% of patients who fail to respond to standard care.
This study demonstrated that a reduction in internal anal sphincter function was more common not only in patients with rectoanal intussusception, but also in those without rectocele.
MAGNIFI-CD has improved operating characteristics compared to other indices assessing MRI scans of perianal fistula activity in CD, and that the new index may be useful as an outcome measure in clinical trials investigating treatment for perianal fistulizing CD.
Study concludes that few of the associated risk factors are modifiable and that clinicians should stress possible outcomes related to urinary dysfunction prior to patients receiving treatment for rectal cancer.
